The Rate Of Blood Coagulation Is Determined Genetically.
In an striving to uncover why some people's blood platelets mass faster than others, a genetic study has turned up a specific grouping of overactive genes that seems to control the process. On the benefit side, platelets are critical for fending off infections and healing wounds. On the down side, they can accelerate heart disease, heart attacks and stroke, the study authors noted.
The current pronouncement regarding the genetic roots driving platelet behavior comes from what is believed to be the largest rehash of the human genetic code to date, according to co-senior study investigator Dr Lewis Becker, a cardiologist with the Johns Hopkins University School of Medicine. "Our results give us a certain set of immature molecular targets, the proteins produced from these genes, to develop tests that could help us identify public more at risk for blood clots and for whom certain blood-thinning drugs may work best or not," Becker said in a Johns Hopkins tidings release.
So "We can even look toward testing new treatments that may haste up how the body fights infection or recovers from wounds". The study findings were published online June 7 in Nature Genetics.
Showing posts with label platelet. Show all posts
Showing posts with label platelet. Show all posts
Thursday, 28 February 2019
Saturday, 6 February 2016
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.
Higher doses of the blood-thinner Plavix were no better at preventing bravery attacks, blood clots or obliteration than the yardstick lower dose in patients who had received artery-opening stents, renewed research shows. The higher dose - understudy the usual amount - was tested in patients with "high platelet reactivity," meaning they failed to reply to the drug at lower doses. Plavix (clopidogrel) helps prevent clots from forming in patients who have dirty platelet reactivity and who have had stents inserted to prop open blocked arteries.
But the supplemental study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to sanctum lead author Dr Matthew Price, who presented the findings Tuesday at the annual congress of the American Heart Association in Chicago. So, the study leaves an important question unanswered: How to review heart patients who don't respond well to Plavix? "It remains erratic to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an effective study to have done but the key issues are that a significant proportion of the patients remained with weighty platelet reactivity even after being on the higher dose".
Previous, smaller studies had indicated that Plavix might have more of an effect if the quantity was doubled. "Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a gamy reactivity standing is associated with poorer outcomes after angioplasty and/or stenting. But until now, a ret rise in the dose of Plavix "has not been tested in a large randomized clinical trial".
Higher doses of the blood-thinner Plavix were no better at preventing bravery attacks, blood clots or obliteration than the yardstick lower dose in patients who had received artery-opening stents, renewed research shows. The higher dose - understudy the usual amount - was tested in patients with "high platelet reactivity," meaning they failed to reply to the drug at lower doses. Plavix (clopidogrel) helps prevent clots from forming in patients who have dirty platelet reactivity and who have had stents inserted to prop open blocked arteries.
But the supplemental study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to sanctum lead author Dr Matthew Price, who presented the findings Tuesday at the annual congress of the American Heart Association in Chicago. So, the study leaves an important question unanswered: How to review heart patients who don't respond well to Plavix? "It remains erratic to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an effective study to have done but the key issues are that a significant proportion of the patients remained with weighty platelet reactivity even after being on the higher dose".
Previous, smaller studies had indicated that Plavix might have more of an effect if the quantity was doubled. "Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a gamy reactivity standing is associated with poorer outcomes after angioplasty and/or stenting. But until now, a ret rise in the dose of Plavix "has not been tested in a large randomized clinical trial".
Subscribe to:
Posts (Atom)